177 related articles for article (PubMed ID: 10333728)
41. Transcriptional regulation by the Wilms' tumour suppressor protein WT1.
Wagner KJ; Roberts SG
Biochem Soc Trans; 2004 Dec; 32(Pt 6):932-5. PubMed ID: 15506928
[TBL] [Abstract][Full Text] [Related]
42. Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice.
Smith SI; Down M; Boyd AW; Li CL
Cancer Res; 2000 Feb; 60(4):808-14. PubMed ID: 10706085
[TBL] [Abstract][Full Text] [Related]
43. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.
Morrison DJ; English MA; Licht JD
Cancer Res; 2005 Sep; 65(18):8174-82. PubMed ID: 16166292
[TBL] [Abstract][Full Text] [Related]
44. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours.
Dallosso AR; Hancock AL; Brown KW; Williams AC; Jackson S; Malik K
Hum Mol Genet; 2004 Feb; 13(4):405-15. PubMed ID: 14681303
[TBL] [Abstract][Full Text] [Related]
45. RNA binding by the Wilms tumor suppressor zinc finger proteins.
Caricasole A; Duarte A; Larsson SH; Hastie ND; Little M; Holmes G; Todorov I; Ward A
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7562-6. PubMed ID: 8755514
[TBL] [Abstract][Full Text] [Related]
46. Physical and functional interaction between the HCMV IE2 protein and the Wilms' tumor suppressor WT1.
Kim JM; Hong Y; Semba K; Kim S
Biochem Biophys Res Commun; 2000 Jan; 267(1):59-63. PubMed ID: 10623574
[TBL] [Abstract][Full Text] [Related]
47. A splice variant of the Wilms' tumour suppressor Wt1 is required for normal development of the olfactory system.
Wagner N; Wagner KD; Hammes A; Kirschner KM; Vidal VP; Schedl A; Scholz H
Development; 2005 Mar; 132(6):1327-36. PubMed ID: 15716344
[TBL] [Abstract][Full Text] [Related]
48. Tumour suppressor gene mutations in humans and mice: parallels and contrasts.
Hooper ML
EMBO J; 1998 Dec; 17(23):6783-9. PubMed ID: 9843483
[TBL] [Abstract][Full Text] [Related]
49. A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X.
Heathcott RW; Morison IM; Gubler MC; Corbett R; Reeve AE
Hum Mutat; 2002 Apr; 19(4):462. PubMed ID: 11933209
[TBL] [Abstract][Full Text] [Related]
50. Exon 9 mutations in the WT1 gene, without influencing KTS splice isoforms, are also responsible for Frasier syndrome.
Kohsaka T; Tagawa M; Takekoshi Y; Yanagisawa H; Tadokoro K; Yamada M
Hum Mutat; 1999; 14(6):466-70. PubMed ID: 10571943
[TBL] [Abstract][Full Text] [Related]
51. Antisense WT1 transcription parallels sense mRNA and protein expression in fetal kidney and can elevate protein levels in vitro.
Moorwood K; Charles AK; Salpekar A; Wallace JI; Brown KW; Malik K
J Pathol; 1998 Aug; 185(4):352-9. PubMed ID: 9828833
[TBL] [Abstract][Full Text] [Related]
52. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation.
Loeb DM; Evron E; Patel CB; Sharma PM; Niranjan B; Buluwela L; Weitzman SA; Korz D; Sukumar S
Cancer Res; 2001 Feb; 61(3):921-5. PubMed ID: 11221883
[TBL] [Abstract][Full Text] [Related]
53. Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product.
Bardeesy N; Pelletier J
Nucleic Acids Res; 1998 Apr; 26(7):1784-92. PubMed ID: 9512553
[TBL] [Abstract][Full Text] [Related]
54. A clinical overview of WT1 gene mutations.
Little M; Wells C
Hum Mutat; 1997; 9(3):209-25. PubMed ID: 9090524
[TBL] [Abstract][Full Text] [Related]
55. Wilms' tumour: connecting tumorigenesis and organ development in the kidney.
Rivera MN; Haber DA
Nat Rev Cancer; 2005 Sep; 5(9):699-712. PubMed ID: 16110318
[TBL] [Abstract][Full Text] [Related]
56. Wilms' tumor 1 and signal transducers and activators of transcription 3 synergistically promote cell proliferation: a possible mechanism in sporadic Wilms' tumor.
Rong Y; Cheng L; Ning H; Zou J; Zhang Y; Xu F; Liu L; Chang Z; Fu XY
Cancer Res; 2006 Aug; 66(16):8049-57. PubMed ID: 16912181
[TBL] [Abstract][Full Text] [Related]
57. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study.
Little SE; Hanks SP; King-Underwood L; Jones C; Rapley EA; Rahman N; Pritchard-Jones K
J Clin Oncol; 2004 Oct; 22(20):4140-6. PubMed ID: 15483024
[TBL] [Abstract][Full Text] [Related]
58. Surgical management and genotype/phenotype correlations in WT1 gene-related diseases (Drash, Frasier syndromes).
Auber F; Lortat-Jacob S; Sarnacki S; Jaubert F; Salomon R; Thibaud E; Jeanpierre C; Nihoul-Fékété C
J Pediatr Surg; 2003 Jan; 38(1):124-9; discussion 124-9. PubMed ID: 12592634
[TBL] [Abstract][Full Text] [Related]
59. Wilms' tumour gene and function.
Hastie ND
Curr Opin Genet Dev; 1993 Jun; 3(3):408-13. PubMed ID: 8353414
[TBL] [Abstract][Full Text] [Related]
60. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis.
Maheswaran S; Englert C; Bennett P; Heinrich G; Haber DA
Genes Dev; 1995 Sep; 9(17):2143-56. PubMed ID: 7657166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
